During its March inspection of drug quality, the Central Drugs Standard Control Organization (CDSCO) found 131 drug samples to be “Not of Standard Quality” (NSQ) and one sample to be “spurious.”
Out of the 131 NSQ samples, 70 were tested and identified by Central Drug Laboratories, while the remaining were tested by State Drugs Testing Laboratories.
Additionally, a sample of the drug Telma 40 (Telmisartan Tablets I.P. 40 mg) was found to be spurious. This was identified by drug regulators in the state of West Bengal.
Telma (Telmisartan) is an antihypertensive medication that works as an angiotensin II receptor blocker and is marketed by Glenmark.
According to Section 17-B of the Drugs and Cosmetics Act, 1940, a spurious drug is defined as a substitute or duplicate of another drug or one that bears the name and label of another product.
Section 16(1)(a) of the same Act defines an NSQ sample as a drug that fails to meet prescribed quality standards or specifications.
Here are the links attached to the CDSCO findings :-